Inflammatory breast cancer (IBC) is an aggressive type of breast cancers (BC). Currently only a few specific genetic biomarkers or signatures have been identified for the disease. However, these genetic signatures are not very representative (Remo et al. 2015). More accurate and reliable biomarkers are in demand to represent the specific phenotypes and to improve the classification of IBC.

A recent study used a network-based approach to analyze the master regulators (MRs) related to IBC pathogenesis (Remo et al. 2015). By using in-silico modeling and cellular network analyses based on gene expression data, master regulators associated with the IBC phenotypes were evaluated.

The study also applied the method of pathway enrichment assessment to predict targets of the potential genes (Remo et al. 2015). In addition, the techniques of immunohistochemistry (IHC) and microarrays were used to examine the expression patterns of the MRs. The combination of these approaches may provide novel methodologies for the discovery of more effective biomarkers for the disease.

References:

Remo A, Simeone I, Pancione M, Parcesepe P, Finetti P, Cerulo L, Bensmail H, Birnbaum D, Van Laere SJ, Colantuoni V, Bonetti F, Bertucci F, Manfrin E, Ceccarelli M. Systems biology analysis reveals NFAT5 as a novel biomarker and master regulator of inflammatory breast cancer. J Transl Med. 2015 May 1;13:138. doi: 10.1186/s12967 015-0492-2.

Leave a Reply

Copyright © 2006-2017 PharmTao.com. All Rights Reserved.

Disclaimer: By using this site, the readers agree that the content on our web pages is for information purpose only. The information provided on our web pages is not intended for diagnosis, or to treat, cure or prevent any diseases, conditions or symptoms, or to endorse any products. Personal directions and the use of health products should be provided by qualified health professionals.

Mind-Body, Personalized, and Systems Medicine